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ABSTRACT
Aminocandin is a new representative of the echinocandins that could potentially affect the cellular
morphology and metabolic status of Candida albicans cells within bioﬁlms. This study investigated the
inﬂuence of a sub-inhibitory concentration (MIC ⁄ 2) of aminocandin on in-vitro growth of C. albicans and
subsequent fungal adherence to plastic surfaces coated with ﬁbronectin or extracellular matrix (ECM)
proteins. Eleven strains of C. albicans were studied, of which six were susceptible and ﬁve were resistant
to ﬂuconazole. All 11 strains were susceptible to aminocandin in vitro, regardless of the culture medium
used for the microdilution method. Aminocandin induced a signiﬁcant (p <0.005) decrease in adherence
when polystyrene was coated with ECM gel (ten strains) or ﬁbronectin (seven strains). Growth in
medium containing aminocandin (MIC ⁄ 2) decreased the adherence of ﬁve (ECM gel) or three
(ﬁbronectin) of the six strains susceptible to ﬂuconazole, and inhibition was observed for all ﬁve (ECM
gel) or four (ﬁbronectin) of the ﬁve ﬂuconazole-resistant strains. Overall, the study demonstrated the
anti-adherent properties of aminocandin with ﬂuconazole-susceptible strains, and suggested that this
activity was at least equivalent with ﬂuconazole-resistant strains. Thus, the ability of aminocandin to
inhibit the ﬁrst step in the development of C. albicans bioﬁlms appeared to be independent of the in-vitro
resistance of C. albicans to ﬂuconazole.
Keywords Adhesion, aminocandin, bioﬁlm, Candida albicans, echinocandins, inhibition
Original Submission: 20 June 2006; Revised Submission: 21 September 2006; Accepted: 22 September 2006
Clin Microbiol Infect 2007; 13: 311–315
INTRODUCTION
Candida infections have been associated with
various invasive indwelling medical devices,
including central venous catheters, joint pros-
theses, and dialysis access and cardiovascular
devices, as well as with superﬁcial devices such as
dentures and dental implants [1,2]. Catheter-
related infections are a major cause of morbidity
and mortality among hospitalised patients, and
microbial bioﬁlms formed on catheter surfaces are
associated with 90% of such infections [3].
Adherence of Candida albicans to implanted med-
ical devices is a prerequisite for colonisation, and
is therefore considered to be a prerequisite for the
process leading to infection. Medical devices
introduced into the body are rapidly coated by
adsorbed proteins [4], and this is followed by
initial attachment of C. albicans blastospores and
the rapid formation of a bioﬁlm layer on the
surface of the device. Individual cells in the
bioﬁlm are embedded within a matrix of fre-
quently slimy, extracellular polymers, and typic-
ally display a phenotype that is very different
from that of planktonic cells. In particular, cells in
bioﬁlms are less susceptible to antifungal agents,
with the degree of resistance increasing in associ-
ation with the maturation of bioﬁlm [1,5–7].
Higher MICs and minimal fungicidal concentra-
tions of amphotericin B, miconazole, ketoconazole
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and itraconazole have been reported for C. albi-
cans cells that have adhered to silicone for 2 h,
compared with planktonic cells, attesting to the
implications of the adherence step [8].
Only a limited number of antifungal drugs can
be used to treat candidiasis associated with
implanted medical devices, and infected devices
generally need to be removed [9]. This type of
infection can result in serious medical complica-
tions and additional treatment costs, and is a
major factor limiting the prolonged use of central
venous catheters. Echinocandins represent a new
class of antifungal drug, with a mode of action
that leads to cell-wall damage [10,11]. The cell
wall is highly involved in the adherence process
of C. albicans, and thus is important in the ﬁrst
step of bioﬁlm formation [5]. Previous results
have shown that low concentrations of caspofun-
gin, which was the ﬁrst member of the echino-
candins licensed for clinical use, can modulate the
in-vitro adherence of C. albicans to polystyrene
coated with extracellular matrix (ECM) [12]. The
present study concerns aminocandin, which is a
new antifungal agent that also belongs to the
echinocandin class [13]. The aim of the study was
to determine whether aminocandin, used at a
concentration below the MIC, could prevent
adherence of C. albicans to plastic coated with
ECM proteins or ﬁbronectin. Theoretically, such
activity could prevent, or at least slow down, the
formation and the maturation of C. albicans bio-
ﬁlms on implanted medical devices.
MATERIALS AND METHODS
Organisms and growth conditions
Eleven strains of C. albicans were studied, of which ﬁve (92,
109, 163, 182 and 240) were clinical isolates from patients with
candidaemia. These strains were identiﬁed by conventional
physiological and morphological methods, e.g., the germ tube
test in serum, agglutination (Bichro-Latex; Fumouze, Levallois
Perret, France) and metabolic properties (API 20C; bio-
Me´rieux, Marcy-L’Etoile, France). C. albicans strain 1066, iso-
lated originally from a patient with septicaemia, was kindly
provided by R. Robert. These six strains were susceptible to
ﬂuconazole (MIC <8 mg ⁄L by Etest). Five other strains were
obtained from IHEM (Biomedical Fungi and Yeasts Collection,
Brussels, Belgium) and were isolated originally from the
human mouth (IHEM-9581, IHEM-9582, IHEM-9584, IHEM-
9586) or human blood (IHEM-10266); these strains had
ﬂuconazole MICs >256 mg ⁄L by Etest.
C. albicans strains were ﬁrst grown for 48 h at 28C on
Sabouraud agar slants (Sanoﬁ Diagnostics Pasteur, Marnes-La-
Coquette, France) to obtain a culture of synchronous station-
ary-phase C. albicans yeast cells [14]. A loopful of this culture
was transferred to 25 mL of Yeast Nitrogen Base medium
(YNB; Difco, Detroit, MI, USA), supplemented with 50 mM
glucose (YNB-glu; Sigma, St Louis, MO, USA), with or without
sub-MICs of aminocandin, and was incubated for 18 h at 37C
without shaking. Before use in the adherence experiments,
blastospores were harvested, washed twice in 0.1 M phos-
phate-buffered saline, pH 7.2 (PBS; bioMe´rieux) and adjusted
to a concentration of 1.5 · 107 blastospores ⁄mL.
MICs of aminocandin
Standard aminocandin powder was kindly provided by
Indevus Pharmaceuticals (Lexington, MA, USA) and was
prepared as a 10 mg ⁄mL stock solution in dimethylsulphox-
ide, and then aliquoted and stored at )80C. MICs of
aminocandin were determined using YNB-Glu medium in
experimental conditions related to adherence assays (MICYNB-
glu). C. albicans inocula were prepared by suspension of cells in
YNB-Glu to a ﬁnal concentration of 104 CFU ⁄mL. MICs were
determined after incubation for 48 h at 37C without shaking
[15]. The MIC was deﬁned as the lowest drug concentration at
which there was no visible fungal growth. Aminocandin was
then used at a sub-MIC, arbitrarily set at MICYNB-glu ⁄ 2. MICs
of aminocandin were also determined using the broth micro-
dilution method in RPMI-1640 medium with L-glutamine, but
without bicarbonate, buffered with 0.165 M MOPS at pH 7
(MICRPMI). All tests were performed in duplicate.
Immobilised ECM proteins
ECM gel (Sigma) or ﬁbronectin (Sigma) were coated on the
wells of polystyrene 96-well tissue culture plates (Evergreen
Scientiﬁc, Los Angeles, CA, USA). ECM gel was coated
according to the manufacturer’s instructions. This gel was
composed primarily of laminin, collagen type IV, heparin
sulphate, proteoglycan and entactin. In brief, the wells of the
microtitre plates were coated with 300 lL of ECM gel
(10 mg ⁄L) or 300 lL of ﬁbronectin (10 mg ⁄L), incubated
overnight at 4C, and washed twice with PBS [15,16].
Adherence of C. albicans to polystyrene coated
with ECM proteins
Adherence experiments were performed in untreated 96-well
tissue culture plates as described previously [15]. Tetrazolium
salt XTT was used to assess the adherence of C. albicans
blastospores to the wells of tissue culture plates, based on the
reduction of XTT tetrazolium to tetrazolium formazan by
mitochondrially active C. albicans blastospores in the presence
of an electron-coupling agent, menadione [12]. In brief,
C. albicans blastospores, with or without pre-incubation for
18 h with a sub-MIC of aminocandin, were added to 96-well
tissue culture plates (1.5 · 107 CFU ⁄mL) in 150 lL of PBS, and
were allowed to adhere to the polystyrene, coated with either
ECM proteins or ﬁbronectin, for 2 h at 37C. Half of the wells
were then washed twice with PBS to remove the non-adherent
yeasts. Then, XTT (Sigma) 300 mg ⁄L and 0.13 mM menadione
(Sigma) were added to all wells. The plates were incubated for
3 h at 37C without shaking, and then gently agitated before
measurement of the XTT formazan concentration at A492 nm
(Micro-plate Reader LP400; Sanoﬁ Diagnostics Pasteur) in
washed and unwashed wells. The adherence capacity of each
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isolate was calculated as a mean of absorbance units in washed
wells divided by absorbance units in unwashed wells. Back-
ground formazan values were determined using plates that
contained only PBS or PBS, XTT and menadione; these values
did not exceed 0.005 absorbance units and were therefore not
signiﬁcant. All experiments were performed twice with six
replicates.
Statistical analyses
An analysis of variance (ANOVA, p <0.05) and a Scheffe´ test
were conducted to determine differences among the test
groups.
RESULTS AND DISCUSSION
All the isolates of C. albicans investigated
were susceptible to aminocandin. Regardless of
the culture medium used for microdilution, the
MICs did not exceed 0.25 mg ⁄L; however,
MICYNB-glu values were higher than MICRPMI
values, with a difference of between one and
four dilutions (Table 1). This is consistent with
previous studies showing that the composition
and the pH of the culture medium can inﬂu-
ence MIC values [17]. The MICRPMI values of
aminocandin were in accordance with the MICs
determined by Andes et al. [13] using similar
experimental conditions.
Previous studies have demonstrated the intrin-
sic resistance of C. albicans in bioﬁlms to the most
commonly used antifungal agents, namely ﬂuc-
onazole and amphotericin B [1,18,19], and it has
been suggested that echinocandins could affect
the cellular morphology and the metabolic status
of C. albicans cells within bioﬁlms. Echinocandins
block the production of 1,3-b-D-glucan, a funda-
mental component of the fungal cell wall, and
cell-wall polysaccharides are important compo-
nents of the Candida bioﬁlm ECM [20]. The
inﬂuence of echinocandins on fungal colonisation
has not yet been well-characterised, although
previous results have demonstrated the ability
of caspofungin to prevent adherence of C. albicans
to polystyrene surfaces coated with proteins. The
present study investigated the effect of amino-
candin on the adherence of C. albicans blasto-
spores to plastic surfaces coated with ECM
proteins or ﬁbronectin.
The aminocandin concentrations tested were
below the MIC, as it has been shown previously
that the effects of sub-inhibitory concentrations of
caspofungin on planktonic cells destined to form
bioﬁlms have important implications [12,21]. The
results of the present study showed that the
growth of C. albicans blastospores in medium
containing a sub-inhibitory concentration
(MIC ⁄ 2) of aminocandin signiﬁcantly inhibited
(Scheffe´’s test, p £0.005) the adherence of yeasts to
plastic coated with ECM proteins or ﬁbronectin
(Figs 1 and 2). Thus, ten (plastic coated with
ECM) and seven (plastic coated with ﬁbronectin)
of the 11 strains investigated were less adherent
(p £0.005) than controls that had not been in
contact with aminocandin during growth.
Aminocandin signiﬁcantly inhibited (p £0.005)
the adherence capacity of all ﬁve strains that were
resistant to ﬂuconazole when polystyrene was
coated with ECM proteins, and four of these
strains when polystyrene was coated with ﬁbro-
nectin. Similarly, the adherence capacity was
inhibited signiﬁcantly for ﬁve and three, respect-
ively, of the six ﬂuconazole-susceptible strains of
C. albicans. Thus the anti-adherent activity of
aminocandin did not appear to be inﬂuenced by
the in-vitro resistance to ﬂuconazole.
The anti-adherent activity of aminocandin can
be explained by the mechanism of action of
echinocandins on the yeast cell wall, which
contains adhesins implicated in the contact of
C. albicans with ﬁbronectin and ⁄ or the different
components of the ECM [5]. Thus, disruption of
the parietal surface could easily perturb the
cellular adherence process.
In a previous study, performed using the same
experimental conditions, the anti-adherent activ-
ity of caspofungin (MIC ⁄ 2) was evaluated with
the same strains of C. albicans, with the results
indicating a reduced anti-adherent activity of
caspofungin when the strains were resistant to
Table 1. MICs of aminocandin for the Candida albicans
strains investigated
C. albicans strains
Aminocandin (mg ⁄L)a
MICYNB-Glu MICRPMI
92 0.25 0.03
109 0.25 0.12
163 0.5 0.03
182 0.25 0.03
240 0.25 0.06
1066 0.25 0.03
9581b 0.25 0.03
9582b 0.125 0.03
9584b 0.125 0.06
9586b 0.125 0.06
10266b 0.25 0.06
aMICs were determined with a broth microdilution method performed in YNB-glu
medium (MICYNB-Glu) or in RPMI medium (MICRPMI). Results are representative of
two separate experiments.
bResistant to ﬂuconazole (MIC >256 mg ⁄L by Etest).
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ﬂuconazole in vitro [12]. This suggested a possible
relationship between in-vitro ﬂuconazole resist-
ance and caspofungin activity. In contrast, ami-
nocandin demonstrated anti-adherent activity
against both ﬂuconazole-susceptible and -resist-
ant strains. These observations suggest that ami-
nocandin could be a good candidate for
preventing the early stages of C. albicans bioﬁlm
development. Further studies are required to
determine the signiﬁcance of preventing bioﬁlm
formation in the clinical setting.
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